Dianthus Therapeutics share price logo

Dianthus Therapeutics

NASDAQ: DNTH

Mid Cap

$75.19

-2.39

(-3.08%)

Live

as on

Dianthus Therapeutics Stock Performance

as on October 15, 2026 at 4:14 am IST

  • Day's Low

    Day's High

    $75.12
    $78.67
    downward going graph

    0.09%

    Downside

    4.63%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $32.22
    $117.88
    downward going graph

    57.15%

    Downside

    56.77%

    Upside

    downward going graph

Dianthus Therapeutics share price movements today

Previous Close
$77.58
Open
$76.75
Volume
262.4K
Market Cap
$4.5B
Day's Low - High
$75.12 - $78.67
52 Week Low - High
$32.22 - $117.88

Dianthus Therapeutics Historical Returns

1 Month Return
-27.96 %
3 Month Return
-23.4 %
1 Year Return
+ 118.26 %
3 Year Return
+ 520.64 %
5 Year Return
0 %

Dianthus Therapeutics Stock Fundamentals & Key Indicators

Check Dianthus Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.5B

EPS (TTM)

-0.13

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-633.62

Industry PE ratio

-11.15

PEG Ratio

104.60

EBITDA

-29.5M

Revenue (TTM)

1.9M

Profit Margin

96.01%

Return On Equity TTM

-3.51%

Dianthus Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Dianthus Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Dianthus Therapeutics image
Dianthus Therapeutics
StrongBuy$4.5BNA-633.6296.01%0.00%
Moderna image
Moderna
Neutral$85.3B-34.84%-28.20-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$128.5B166.75%29.4586.04%0.00%
Regeneron image
Regeneron
Buy$78.5B35.55%17.8384.86%0.49%

Stock Returns calculator for Dianthus Therapeutics Stock including INR - Dollar returns

The Dianthus Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Dianthus Therapeutics investment value today

Current value as on today

₹2,26,683

Returns

₹1,26,683

(+126.68%)

Returns from Dianthus Therapeutics Stock

₹1,11,535 (+111.53%)

Dollar Impact

₹15,149 (+15.15%)

Analyst Recommendation on Dianthus Therapeutics Stock

Based on 11 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 11 analysts, 100% of analysts recommend a 'BUY' rating for Dianthus Therapeutics. Average target price of $140.8

Dianthus Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Dianthus Therapeutics.

What analysts predicted

46.6%UPSIDE

Target Price

$140.8

Current Price

$75.19

Analyzed by

11 Analysts

High

$200

Target

$140.80

Low

$122

Dianthus Therapeutics target price $140.8, a slight upside of 46.6% compared to current price of $75.19. According to 11 analysts rating.

Indian Investors' Interest in Dianthus Therapeutics Stock

Search interest for Dianthus Therapeutics Stock has decreased by -45% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-45% versus previous 30 day period

Dianthus Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
1
2
1
1
0
0
0
0
0
Gross Profit
0
1
2
1
1
0
0
0
0
0
Operating Income
-17
-22
-29
-31
-33
-34
-40
-69
-46
-61
EBITDA
-13
-17
-25
-28
-29
-31
-36
98
-40
-50
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-13
-17
-25
-28
-29
-31
-36
97
-40
-50
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-13
-17
-25
-28
-29
-31
-36
97
-40
-50
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
83.59%
100.00%

Dianthus Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
1
6
2
6
2
Gross Profit
0
0
-1
-1
1
6
2
6
2
Operating Income
-35
-59
-82
-78
-13
-29
-48
-101
-177
EBITDA
-35
-56
-74
-72
-11
-28
-43
-84
-161
Interest Expense
-
-
-
3
-
-
-
-
-
Depreciation
0
0
1
1
2
0
0
0
0
Income Before Tax
-35
-57
-76
-74
-13
-28
-43
-84
-162
Income Tax Expense
0
-
-
-
-
-
-
-
-
Net Income
-35
-57
-76
-74
-13
-28
-43
-84
-162
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%

Dianthus Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-13
-17
-25
-28
-29
-31
-36
-64
-40
-50
Operating Cash Flow
-14
-14
-21
-27
-27
-23
-30
-46
-28
-48
Investing Cash Flow
-5
1
-259
-23
14
26
-201
37
-133
-478
Financing Cash Flow
217
-2
0
39
0
0
274
4
739
10
Change in Cash
197
-15
-280
-10
-12
3
42
-4
576
-517

Dianthus Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-35
-57
-76
-74
-71
-28
-43
-84
-162
Operating Cash Flow
-22
-41
-57
-64
-59
-29
-36
-78
-129
Investing Cash Flow
-2
-91
1
-10
43
-59
20
-286
-122
Financing Cash Flow
71
142
62
67
89
96
133
255
280
Change in Cash
47
6
6
-6
73
7
116
-109
28

Global Institutional Holdings in Dianthus Therapeutics

Check out the Institutions with significant holdings in Dianthus Therapeutics.

Funds
Holdings
Peter Kolchinsky
4.67%
Vanguard
4.65%
Peter Harwin
4.54%
iShares
3.54%
VANGUARD INDEX FUNDS
3.53%
See all

Dianthus Therapeutics News & Key Events

  • img

    Today's Timeline - 12 June

    Sat, 02:43 AM

    -

    Dianthus reports 75% improvement in CIDP trial, exceeding expectations, leading to an 8% stock increase.

Insights on Dianthus Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 284.0K → 761.0K (in $), with an average increase of 38.9% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, DNTH has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 723.8% return, outperforming this stock by 605.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, DNTH stock has moved down by -28.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 97.90M → -50.21M (in $), with an average decrease of 82.3% per quarter

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
OrganisationDianthus Therapeutics
Headquarters7 Times Square, New York, NY, 10036, US
IndustryBiotechnology
CEOMarino Garcia

Key Management of Dianthus Therapeutics

Name

Title

Ms. Kristina Maximenko

Chief People Officer

Dr. Simrat Randhawa M.B.A., M.D.

Executive VP and Head of R&D

Ms. Jennifer Davis Ruff

VP and Head of Investor Relations & Corporate Affairs

Mr. Adam M. Veness Esq.

Senior VP, General Counsel & Secretary

Mr. Judson Taylor

Senior VP & Head of Technical Operations

Ms. Rashieda Gluck

Head of Clinical Development Operations

Mr. Scott Nogi M.B.A.

Head of Business Operations

Mr. Marino Garcia M.B.A.

President, CEO & Director

Mr. Ryan Savitz

Executive VP, CFO, Chief Business Officer & Treasurer

Mr. Edward G. Carr

Senior VP & Chief Accounting Officer

FAQs

What is Dianthus Therapeutics share price today?

Dianthus Therapeutics share price today is $75.19 as on . Dianthus Therapeutics share today touched a day high of $78.67 and a low of $75.12.

What is the 52 week high and 52 week low for Dianthus Therapeutics share?

Dianthus Therapeutics share touched a 52 week high of $117.88 on and a 52 week low of $32.22 on . Dianthus Therapeutics stock price today i.e. is trending at $75.19,which is 36.21% down from its 52 week high and 133.36% up from its 52 week low.

What is Dianthus Therapeutics's market capitalisation today?

Dianthus Therapeutics market capitalisation is $0.00T as on .

How to invest in Dianthus Therapeutics Stock (DNTH) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Dianthus Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Dianthus Therapeutics Stock (DNTH) from India?

Indian investors can start investing in Dianthus Therapeutics (DNTH) shares with as little as ₹95.13999938964844 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹951.40 in Dianthus Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Dianthus Therapeutics share’s latest price of $75.19 as on October 14, 2026 at 10:44 pm IST, you will get 0.1330 shares of Dianthus Therapeutics. Learn more about fractional shares .